Drug Trial Radar · NCT05650385
A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
68
Planned (sponsor's estimate)
Start
Dec 2022
Primary completion
Dec 2023
Study completion Oct 2025
Sponsor
- Lead sponsor
- Tasly Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of B1962, a PD-L1/VEGF bispecific antibody fusion protein, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of two parts: a once-weekly (QW) dosing phase and a biweekly (Q2W) dosing phase, which will explore the possibility of Q2W dosing of B1962 based on the PK data obtained in the QW phase. The study will determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for B1962 as a single agent.
Conditions
- Neoplasms Malignant
Interventions
B1962Drug
B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT AssessmentTime frame: From Day1 to Day15 after first dose of B1962
- AE AssessmentTime frame: From first dose of B1962 until 28 days after the last dose of B1962.
- 12-lead ECG AssessmentTime frame: From first dose of B1962 until 28 days after the last dose of B1962.
- Eastern Cooperative Oncology Group score AssessmentTime frame: From first dose of B1962 until 28 days after the last dose of B1962.
- Determine the maximum tolerated dose (MTD)Time frame: From first dose of B1962 until 28 days after the last dose of B1962
- Determine the recommended phase II dose (RP2D)Time frame: From first dose of B1962 until 28 days after the last dose of B1962
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.